Rapidly bring the
candidates to commercialization
Dr. Wan Yakun, the founder of Loqi Biology, took the lead in establishing the first nanoantibody research and development team in China. He has been deeply engaged in the field of nanoantibody research for many years, and has rich experience in the research and development of nanoantibody projects. His team has participated in the development of many nanoantibody projects. The team is recognized as the "leader" in the development of nanoantibody in China. At present, the team has completed the immunization of more than 250 camels, involving more than 400 biological targets. The mature technical platform and rich project experience can ensure that the specific antibody molecules of the intended target can be obtained within 2-3 months.
The high efficiency of antibody screening gives Rocky Biology a flexible and independent project layout ability. In the face of the situation that domestic biopharmaceuticals are mostly in the process of catching up with international hot targets, and the repeatability is relatively high. Based on the mature nanoantibody development platform, Loki Biologics has rich independent research and development pipelines, many targets, and a wide layout, with high project autonomy and research and development freedom. The 2-3 month screening cycle also greatly ensures the rapid follow-up of hot projects.
The company has successfully constructed immune library, synthetic library and non-immune library in the early stage.
1）Immune library: amplify the VHH gene of camel heavy chain antibody by immunizing the corresponding antigen of camel, and establish a phage-displayed nanoantibody immune library. We have constructed 250 phage-displayed nanoantibody immune libraries with the size of 10E8-10E9 CFU. The nano antibody obtained by screening has excellent heat resistance, strong specificity, high affinity, and the equilibrium dissociation constant kD value is generally at the level of nM. The obtained nanoantibodies will become a valuable resource for the application of therapeutic nanoantibodies in the next step.
2）Natural library: We build a natural non-immune phage display library with huge storage capacity and rich diversity by taking 24 blood samples of camels without artificial immunity and one spleen from another non-immune camel. The storage capacity is 6.86 × 10E11 CFU is the largest known natural phage display nanoantibody library. Using procalcitonin PCT and human neutrophil gelatinase-associated lipid carrier protein NGAL as target proteins, the corresponding specific nanoantibodies were successfully screened from the library, and the thermal stability and affinity of the antibodies showed the same level as the nanoantibodies from the immune library. The above work was published in the Journal of Nanobiotechnology and applied for a national invention patent.
3）Synthetic library: We successfully synthesized a phage display library with a random combination of amino acid sequences in the CDR3 region and without cysteine and termination codon, using the nanoantibody conservative framework cAbBCII10 as the VHH skeleton structure, through nested PCR assembly. The library capacity is 1.65 × 10E9 CFU, the library is rich in diversity. Using human prealbumin PA and human neutrophil gelatinase-associated lipid carrier protein NGAL as target proteins, corresponding nanoantibodies were successfully screened. The antibody has high affinity, strong specificity and good heat resistance. The above work was published in the Journal of Translational Medicine and applied for a national invention patent.